Stocktoria
ABVC BIOPHARMA, INC. ABVC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2004-11-09
ABVC BIOPHARMA, INC. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296,000 | $509,589 | $152,430 | $969,783 | $355,797 | $483,045 | $701,719 | $6,956 | — | — |
| Gross profit | — | $508,826 | -$149,607 | $683,368 | $350,711 | $464,329 | $681,582 | -$178,324 | — | — |
| R&D expense | $121,085 | $179,272 | $1.1M | $2.7M | $1.0M | $549,658 | $1.0M | $988,721 | $3.2M | $3.2M |
| SG&A expense | $2.9M | $2.3M | $5.4M | $6.1M | $5.7M | $4.3M | $3.1M | $1.6M | $811,685 | $707,142 |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.1M | -$11.7M | -$8.5M | -$3.5M | -$2.8M | -$4.1M | -$4.0M |
| Interest expense | — | — | $1.3M | $293,968 | $227,210 | $405,032 | $482,014 | $462,751 | $103,460 | $74,960 |
| Income tax | $24,154 | -$110,539 | $256,006 | $797,778 | $825,024 | -$220,352 | -$77,041 | -$365,097 | $830 | $830 |
| Net income | -$7.9M | -$4.9M | -$7.8M | -$16.4M | -$12.8M | -$10.6M | -$3.9M | -$6.1M | -$4.2M | -$4.1M |
| EPS (diluted) | $-0.39 | $-0.27 | $-0.73 | $-2.10 | $-0.21 | $-0.20 | — | $-0.01 | $-0.01 | $-0.01 |
| Operating cash flow | -$3.0M | -$1.8M | -$4.2M | -$7.4M | -$7.6M | -$4.6M | -$3.1M | -$900,531 | -$1.5M | -$1.6M |
| Free cash flow | — | — | -$4.2M | -$7.5M | -$7.6M | — | — | — | — | — |
| Cash & equivalents | $681,480 | $248,382 | $60,155 | $85,265 | $5.8M | $4.3M | $144,295 | $226,688 | $350,257 | $204,851 |
| Inventory | — | — | — | — | $25,975 | — | — | $1,318 | — | — |
| Total assets | $21.1M | $7.5M | $7.8M | $9.6M | $13.7M | $11.6M | $6.9M | $5.9M | $2.6M | $2.8M |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M | $8.9M | $7.1M | $11.3M | $4.4M | $4.1M |
| Shareholders' equity | $13.3M | $1.2M | $1.6M | $3.2M | $8.9M | $3.4M | -$150,964 | -$5.7M | -$1.8M | -$1.4M |
Growth · year-over-year · Revenue CAGR 70.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -41.9% | +234.3% | -84.3% | +172.6% | -26.3% | -31.2% | +9988.0% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.